Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders
Sponsor: Seaside Therapeutics, Inc.
A PHASE2 clinical study on Autism Spectrum Disorders, this trial is completed. The trial is conducted by Seaside Therapeutics, Inc. and has accumulated 8 data snapshots since 2009. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seaside Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .